Zimmer Biomet Holdings, Inc. (ZBH) — Analysis Summary
Zimmer Biomet Holdings, Inc. (ZBH) has a market cap of $18.97B with year-over-year revenue growth of +7.2%. Net margin stands at 8.6%. The stock trades at a P/E ratio of 23.5.
Key Takeaways
- Revenue changed +7.2% year-over-year
- Net margin of 8.6%
- P/E ratio of 23.5
Compared to other companies in the ORTHOPEDIC, PROSTHETIC & SURGICAL APPLIANCES & SUPPLIES sector, ZBH posted revenue growth of +7.2% and trades at a P/E of 23.5.
Zimmer Biomet Holdings, Inc. (ZBH)
UPDATED — ET · MARKET DATA POLYGON · FINANCIALS SEC EDGAR
Red Flags & WarningsNo Major Flags
No major credit, margin, or trend red flags were triggered from the latest filings.
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly two-thirds of total revenue is derived from sales of large joints; another fourth comes from extremities, trauma, sports medicine, and related surgical products. The firm spun out its dental and spine businesses in 2022.
Sector
ORTHOPEDIC, PROSTHETIC & SURGICAL APPLIANCES & SUPPLIES
Employees
17,000
Headquarters
WARSAW, IN
Exchange
XNYS
Systematic competitive advantage assessment based on 4yr data
This assessment is based on quantitative analysis of historical financial data and does not constitute investment advice. Moat ratings may change with industry and competitive dynamics.
First version surfaces recent SEC Forms 3, 4, and 5 activity. It does not yet parse individual buy/sell transactions.
Capital Structure
Cash Flow
Annual Dividend/Share
$0.96
Dividend Yield
0.95%
Dividend History
Disclaimer: This is not financial advice. Data sourced from SEC EDGAR and Polygon.io. Past performance does not guarantee future results. Always conduct your own research before making investment decisions.